Effect of cyclooxygenase-2 inhibitor (celecoxib) on the infarcted heart in situ.
| Autor: | Yamamoto T; Huntington Medical Research Institutes, Department of Experimental Cardiology, Pasadena, Calif 91101, USA., Kakar NR, Vina ER, Johnson PE, Bing RJ |
|---|---|
| Jazyk: | angličtina |
| Zdroj: | Pharmacology [Pharmacology] 2001 Jul; Vol. 63 (1), pp. 28-33. |
| DOI: | 10.1159/000056109 |
| Abstrakt: | Several attempts have been made to replace aspirin with compounds without gastric toxicity; a cyclooxygenase-2 (COX-2) inhibitor, celecoxib, and a nitric oxide-aspirin, NCX-4016, have been developed for this purpose. This paper compares effects of celecoxib, NCX-4016 and aspirin on production of prostacyclin (PGI2) and thromboxane A2 (TXA2) and activation of the inducible form of nitric oxide synthase (iNOS) in infarcted heart in situ. Aspirin was most effective in reducing myocardial PGI2 synthesis and formation of TXA2. Myocardial effects of celecoxib resemble those of NCX-4016, although the two compounds have different modes of action. (Copyright 2001 S. Karger AG, Basel) |
| Databáze: | MEDLINE |
| Externí odkaz: |
|